市場調査レポート

スリランカの製薬企業の将来展望 (2015年) :単なる輸入業者・流通業者を超えた存在への成長

Sri Lanka Pharma Market Outlook 2015: More beyond Importers & Distributors

発行 MP Advisors 商品コード 324901
出版日 ページ情報 英文 29 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
スリランカの製薬企業の将来展望 (2015年) :単なる輸入業者・流通業者を超えた存在への成長 Sri Lanka Pharma Market Outlook 2015: More beyond Importers & Distributors
出版日: 2015年01月26日 ページ情報: 英文 29 Pages
概要

スリランカの製薬産業の規模はまだ非常に小さく、国内系企業が自律的に機能して、外資系企業に立ち向かえるような水準には達していません。逆に言えば、スリランカは医薬品の国内向け/輸出向け製造拠点として、飛躍的に成長する可能性を秘めています。同国にとっても、産業構造を多様化して経済発展を遂げるのに際して、製薬産業の発達は非常に有益と言えます。スリランカでは無料医療制度があるため、製薬業界は政府部門が主導していますが、そこでカバーしきれない分を民間部門が補完しています。同国の医療支出額は近年 (2005〜2010年)、11%もの年平均成長率 (CAGR) で成長していますが、政府部門以上に民間部門が急拡大しています。

当レポートでは、スリランカの医薬品市場および製薬産業の最新動向について分析し、同国の概況や医療部門の発達状況、各種疾患の発症率・有病率、今後の市場機会の見通し、政府・民間部門による医薬品の供給体制と入手状況、国内系・外資系企業のプロファイル、現在の規制体制といった情報を盛り込んでお届けいたします。

目次

  • エグゼクティブサマリー
  • 市場概要:スリランカ
    • 人口統計
    • 経済
    • 各種疾患の有病者数・発症件数
    • 医療制度:市場機会・課題
  • スリランカの医薬品市場の概要
    • 医薬品市場の規模と、過去の成長率データ
    • 基礎的資源の利用可能性および支援制度
    • 今後の成長率
  • 医薬品の供給と購入可能性 (アクセシビリティ)
    • 政府 (MSD) のSPC調達を通した病院向け物資の購入
    • 民間市場
  • スリランカ国内の医薬品製造の現状
    • 国内系企業
    • 外資系企業
  • 規制・価格・保険の体制

図表一覧

目次
Product Code: 4480

With the recent development, Sri Lanka's aim of developing a pharma industry should be to penetrate the global market since the internal market is not sufficient for any big firm to operate at optimum levels. According to a report published by Indian Council on International Relations in Dec. ‘14, the global market of pharma is about $1trillion, and India's export of pharma products in 2013 amounted to $13bn, where as Sri Lanka was nil. Hence, pharma industry offers a very valuable opportunity for Sri Lanka to diversify its manufacturing and export base and thereby reach the goal of upper middle income country by 2020 and a rich country by 2035.

Sri Lanka's free healthcare policy practiced by successive governments ensures that this arena continues to be dominated by the government sector. Meanwhile, the relatively smaller public counterpart, i.e. the private sector has increasingly contributed towards serving the healthcare needs of the country. Sri Lanka's total expenditure on health has increased by ~11%, CAGR (2005-2010), and this has been driven by both private- (+12%) and government-sector (+10%) spending. Notwithstanding the state sector's dominance, private sector expenditure on health has continued to rise, contributing an estimated 55% to total expenditure.

In this report, we highlight the economy, demography, past and emerging trend of pharma industry, and availability of basic resources. This report also provides current disease prevalence and incidence along with the country's healthcare system and also discuss about future market opportunities. Furthermore, the report explains current medical supply and product accessibility in Govt. and Private sectors along with physicians prescribing pattern and price control. Local manufacturing and role of Govt. support to local manufacturers, regulatory and insurance framework are also discussed in this report.

Table of Contents

  • 1. Executive Summary
  • 2. Overview: Sri Lanka
    • a. Demography
    • b. Economy
    • c. Disease prevalence and Incidence
    • d. Healthcare systems - Opportunities & Challenges
  • 3. Synopsis of Sri Lankan Pharmaceutical Market
    • a. Pharmaceutical Market Size and Historical Growth data
    • b. Availability of Basic Resources and Support Systems
    • c. Future Growth
  • 4. Medicine Supply and Accessibility
    • a. Government (MSD) purchase of hospital supplies through SPC Tender
    • b. Private market
  • 5. Current Status of Pharmaceutical Manufacturing in Sri Lanka
    • a. Local Players
    • b. Foreign players
  • 6. Regulatory, Pricing, Insurance Framework

Tables

  • Table-1: Type of Institutions and Availability of Patients Beds
  • Table-2: Fund Allocation for Pharmaceutical Purchase
  • Table-3: Observation from the Study of SPC-DHS Supply Tender
  • Table-4: Testing at the NDQAL
  • Table-5: Sri Lanka's Medical & Pharmaceutical Import
  • Table-6: Country Wise Market Imports
  • Table-7: Number of Products Manufactured Locally
  • Table-8: Top 20 Companies in the Private Market- Sri Lanka
  • Table-9: Drug Products Registered With CDDA
  • Table-10: Sri Lanka CDDA Drug Approval Timeline

Figure

  • Figure-1: Distribution of Years of Life Lost By Causes
  • Figure-2: Risk Factors and Determinants of NCDs
  • Figure-3: Sri Lanka: Total Pharmaceutical Market
  • Figure-4: IMS Data - 2013: Therapy Areas, By Volume & Value
  • Figure-5: Future Growth - 2012-2020: Therapy Areas, By Value
Back to Top